Cargando…

Bell's palsy after Sputnik V COVID‐19 (Gam‐COVID‐Vac) vaccination

A possible association between Bell's palsy and COVID‐19 vaccination has been suggested previously. Here, we report two cases of facial nerve hemiparalysis following the Sputnik V COVID‐19 vaccination in a 27‐year‐old female patient and a 58‐year‐old male patient who were both clinically diagno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mirmosayyeb, Omid, Barzegar, Mahdi, Rezaei, Mina, Baharlouie, Negar, Shaygannejad, Vahid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867017/ https://www.ncbi.nlm.nih.gov/pubmed/35228880 http://dx.doi.org/10.1002/ccr3.5468

Ejemplares similares

Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac)
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Re: Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination: Author's response
por: Pereson, Matías J., et al.
Publicado: (2022)

Assessment of the humoral immunity induced by Sputnik V Covid-19 vaccine (GAM-COVID-VAC) in healthcare workers()
por: Cordova, Ezequiel, et al.
Publicado: (2022)

WCN23-0034 A COMPARISON OF GAM-COVID-VAC (SPUTNIK V) VACCINE IMMUNOGENICITY IN HEMODIALYSIS PATIENTS AND NON-RENAL SUBJECTS
por: PARSHINA, E., et al.
Publicado: (2023)

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients
por: Laham, Gustavo, et al.
Publicado: (2022)

ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance
por: Montalti, Marco, et al.
Publicado: (2021)

ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance
por: Di Valerio, Zeno, et al.
Publicado: (2022)

Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis
por: Pereson, Matías J., et al.
Publicado: (2022)

Screening neuromyelitis optica patients for COVID-19 infection
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Gam-COVID-Vac (Sputnik V) and Pfizer-BioNTech Vaccines Adverse Events following Immunization in Patients Affected by Parkinson’s Disease and Multiple Sclerosis: A Longitudinal Study
por: Soldà, Giorgia, et al.
Publicado: (2022)

Characteristics of COVID-19 disease in multiple sclerosis patients
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Severe Persistent Eczema in a Recipient of the Gam-COVID-Vac vaccine
por: Ameri, Maryam, et al.
Publicado: (2022)

Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study
por: Barzegar, Mahdi, et al.
Publicado: (2021)

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review
por: Mirmosayyeb, Omid, et al.
Publicado: (2023)

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2020)

Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 vaccine; a case report
por: Mirmosayyeb, Omid, et al.
Publicado: (2021)

Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis
por: Barzegar, Mahdi, et al.
Publicado: (2022)

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review
por: Barzegar, Mahdi, et al.
Publicado: (2021)

T-Cell Immunity in COVID-19-Recovered Individuals and Individuals Vaccinated with the Combined Vector Vaccine Gam-COVID-Vac
por: Krechetov, Sergey Petrovich, et al.
Publicado: (2023)

The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac
por: Tonnara, Giuseppe, et al.
Publicado: (2022)

The Features of COVID-19’s Course and the Efficacy of the Gam-COVID-Vac Vaccine in Patients with Paroxysmal Nocturnal Hemoglobinuria
por: Ptushkin, Vadim, et al.
Publicado: (2023)

Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

Mild Facial Paresis in a Recipient of Gam-COVID-Vac Vaccine: A Case Report
por: Mahmoudi Hamidabad, Negin, et al.
Publicado: (2022)

Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina
por: González, Soledad, et al.
Publicado: (2021)

Predictors of Catching COVID-19 Infection during Pandemic Stage in Patients with Multiple Sclerosis (MS)
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2022)

Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS)
por: Mirmosayyeb, Omid, et al.
Publicado: (2021)

Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset
por: Sadeghi-Bahmani, Dena, et al.
Publicado: (2022)

Demographic and Clinical Characteristics of Familial and Sporadic Multiple Sclerosis Patients
por: Mokhtari, Shahrzad, et al.
Publicado: (2023)

Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based study
por: Barzegar, Mahdi, et al.
Publicado: (2022)

CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series
por: Ebrahimi, Narges, et al.
Publicado: (2023)

SG-APSIC1049: Immunogenicity of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in seropositive and seronegative adults
por: Stoma, Igor, et al.
Publicado: (2023)

Managing anxiety among multiple sclerosis patients during COVID-19 pandemic
por: Adibi, Iman, et al.
Publicado: (2021)

Bell’s palsy following COVID-19 vaccination
por: Colella, Giuseppe, et al.
Publicado: (2021)

Editorial: CNS autoimmune disorders and COVID-19
por: Mirmosayyeb, Omid, et al.
Publicado: (2023)

Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study
por: Stoma, Igor, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1ijcsabv41t84lbg071udpjs4j